Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-31 @ 4:14 PM
Study NCT ID:
NCT06118658
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-07
First Post:
2023-10-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Sponsor:
China Medical University, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Adjuvant-GC/EGJ/CRC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None